KSM-66® Ashwagandha Research
Sereniva Gummies provide 600 mg of KSM-66® ashwagandha root extract per two-gummy serving. KSM-66® is a full-spectrum root extract standardized to at least 5% total withanolides. The studies below evaluated KSM-66® or ashwagandha extracts in adults; they did not study Sereniva Gummies themselves. They are presented so you can evaluate the evidence, including its limits, directly.
A branded, full-spectrum Withania somnifera root extract. Sereniva provides the same 600 mg daily KSM-66® dose used in several short-term adult studies; this does not mean Sereniva Gummies themselves were the study product or that a clinical outcome is guaranteed.
Each study below used a defined extract and population. Sereniva Gummies themselves were not the intervention in these studies.
In a 60-day, randomized, double-blind, placebo-controlled trial, 64 adults reporting high stress took KSM-66® 300 mg twice daily or placebo. The study reported statistically significant between-group differences in perceived-stress measures and morning serum cortisol. This was a short-term study of the branded extract, not a treatment study of Sereniva Gummies.
View full studyThis eight-week, randomized, double-blind, placebo-controlled study enrolled 60 adults with insomnia. Participants received KSM-66® 300 mg twice daily or placebo; the investigators assessed self-reported and objective sleep measures. It is a small, short-duration study and does not establish that a dietary supplement treats insomnia.
View full studyA small, eight-week randomized, double-blind, placebo-controlled trial in 50 adults with mild cognitive impairment evaluated KSM-66® 300 mg twice daily or placebo and assessed memory and selected cognitive tests. The findings are specific to that studied population and should not be interpreted as evidence that Sereniva treats cognitive impairment.
View full studyA 2021 systematic review and meta-analysis of five randomized controlled trials (400 adults) found a small but statistically significant pooled effect on sleep outcomes. Effects were more prominent in studies using at least 600 mg/day, at least eight weeks, and participants with insomnia. The authors’ results remain limited by the small number and short duration of available studies.
View full studyThis is health education, not individualized medical advice.
Clinical studies of ashwagandha are generally short term, and long-term safety is not established. NIH notes possible thyroid effects, medication interactions, and rare reports of liver injury. People who are pregnant or nursing, take medication, or have a medical condition should consult a qualified healthcare professional before using Sereniva; stop use and seek care if an adverse reaction occurs.
View full studyFormulated with the studied ingredients at the researched doses.
* These statements have not been evaluated by the Food and Drug Administration. Sereniva Gummies are not intended to diagnose, treat, cure, or prevent any disease.